Real-world trends in diagnosis, treatment, and survival of non-small cell lung cancer in Vietnam
In Vietnam, lung cancer survival more than doubled over six years as doctors increasingly used genetic testing to prescribe targeted therapies, showing real-world gains in underserved regions.
In a cohort of 3,087 NSCLC patients in Vietnam, median overall survival nearly doubled from 12 to 21.7 months over six years, driven by increased molecular testing and targeted therapy adoption. This large LMIC real-world dataset demonstrates meaningful precision oncology implementation gains in an underserved population and provides a benchmark for similar settings.
What the study was
- Study design
- Retrospective observational cohort study
- Population
- Consecutive adults with histologically confirmed NSCLC, Nghe An Oncology Hospital, Vietnam, 2018-2024
- Sample size
- 3087
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- BMC Cancer
Why it surfaced
Large real-world LMIC cohort (n=3,087) documents substantial OS improvement in NSCLC over 6 years; provides rare prospectively tracked benchmark from Southeast Asian population with historically limited oncology data; design quality 2 for large well-characterized retrospective cohort.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.